Provectus生物制药公布了一项临床前研究结果，显示其口服候选药物PV-10在膀胱癌模型中展现出抗肿瘤活性。值得注意的是，在研究的终点，长期存活的个体中未观察到肉眼可见的膀胱肿瘤。
Provectus生物制药公布了一项临床前研究结果，显示其口服候选药物PV-10在膀胱癌模型中展现出抗肿瘤活性。值得注意的是，在研究的终点，长期存活的个体中未观察到肉眼可见的膀胱肿瘤。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.